Boehringer Ingelheim
boehringer-ingelheim.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
2,282
Active
97
Phase 3
399
Total enrollment
15,710,911
Pipeline matrix
Showing 40 of 105 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Spesolimab | — | 23 | |||||
| Zongertinib | — | — | — | 14 | |||
| Empagliflozin | — | 56 | |||||
| Carboplatin | — | — | — | 10 | |||
| Nerandomilast | — | — | — | — | 9 | ||
| Pembrolizumab | — | — | — | 7 | |||
| Vicadrostat | — | — | — | 6 | |||
| Survodutide | — | — | — | 13 | |||
| Obrixtamig | — | — | — | 4 | |||
| Etoposide | — | — | — | — | 4 | ||
| Atezolizumab | — | — | — | 4 | |||
| BI 1291583 | — | — | — | 15 | |||
| Cisplatin | — | — | — | 5 | |||
| BI 764198 | — | — | — | 11 | |||
| Pemetrexed | — | — | — | 9 | |||
| tenecteplase | — | — | — | — | 6 | ||
| Prednisone | — | — | — | 3 | |||
| BI 690517 | — | — | — | 9 | |||
| nivolumab | — | — | — | — | 2 | ||
| Nerandomilast formulation 1 | — | — | — | — | — | 1 | |
| Nerandomilast formulation 2 | — | — | — | — | — | 1 | |
| Standard of care treatment | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| BI 3034701 | — | — | — | — | 4 | ||
| BI 1815368 | — | — | — | — | 6 | ||
| BI 3000202 | — | — | — | — | 6 | ||
| BI 1015550 | — | — | — | 19 | |||
| trastuzumab | — | — | — | 5 | |||
| Brigimadlin | — | — | — | — | 5 | ||
| BI 1584862 | — | — | — | — | 6 | ||
| BI 765423 | — | — | — | — | 3 | ||
| BI 3720931 | — | — | — | — | — | 2 | |
| BI 771716 | — | — | — | — | 2 | ||
| Capecitabine | — | — | — | — | — | 2 | |
| BI 764524 | — | — | — | — | — | 2 | |
| BI 3802876 | — | — | — | — | 2 | ||
| Pegcetacoplan | — | — | — | — | — | 1 | |
| Sham comparator to BI 771716 | — | — | — | — | — | 1 | |
| BI 3032950 intravenous | — | — | — | — | — | 1 |
65 more active programs hidden
Next readouts
- 2024-07-16
- 2025-06-11
- 2026-04-27
- 2026-07-09
- 2026-07-17
- 2026-07-23
- 2026-07-24
- 2026-07-31
- 2026-08-04
- 2026-08-04
Top conditions
- Healthy803
- Pulmonary Disease, Chronic Obstructive232
- Diabetes Mellitus, Type 2126
- Hypertension122
- HIV Infections67
- Asthma62
- Neoplasms57
- Carcinoma, Non-Small-Cell Lung56
Frequently asked questions about Boehringer Ingelheim
- How many clinical trials does Boehringer Ingelheim have on ClinicalTrials.gov?
- Boehringer Ingelheim is listed as the lead sponsor on 2,282 clinical trials in ClinicalTrials.gov, 97 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boehringer Ingelheim's trials are in Phase 3?
- 399 of Boehringer Ingelheim's trials are in Phase 3, spread across 105 active drug programs.
- What therapeutic areas does Boehringer Ingelheim focus on?
- Boehringer Ingelheim's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Type 2, Hypertension, HIV Infections.
- When are Boehringer Ingelheim's next clinical trial readouts?
- Boehringer Ingelheim has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated”, expected around 2024-07-16.